Changes to oxfendazole chiral kinetics and anthelmintic efficacy induced by piperonyl butoxide in horses.
Authors: Sánchez Bruni S F, Fusé L A, Moreno L, Saumell C A, Alvarez L I, Fiel C, McKellar Q A, Lanusse C E
Journal: Equine veterinary journal
Summary
# Editorial Summary: Enhancing Oxfendazole Efficacy Through Metabolic Inhibition Rising anthelmintic resistance in equine parasites demands novel pharmacological strategies, and this 2005 study investigated whether piperonyl butoxide (PB)—a cytochrome P450 inhibitor—could augment oxfendazole (OFZ) performance in naturally parasitised horses. Researchers administered OFZ alone (10 mg/kg) or combined with PB (63 mg/kg) to 15 ponies, then monitored plasma drug concentrations over 120 hours and assessed faecal egg count reduction and larval recovery post-treatment. Co-administration of PB dramatically improved OFZ's pharmacokinetic profile: maximum plasma concentration increased threefold and area under the curve increased fivefold, whilst the active metabolite fenbendazole more than tripled in systemic exposure. These pharmacokinetic improvements translated directly into superior clinical efficacy, with the OFZ + PB combination achieving 100% efficacy against adult nematodes compared to OFZ alone, and reducing cyathostome L3 larvae efficacy from 94% to 98.7%, alongside a ninefold reduction in L4 larvae recovery. For practitioners managing resistance-compromised operations, metabolic inhibitors represent a tangible opportunity to restore benzimidazole potency without switching drug classes entirely—though the practical challenge of delivering dual-agent protocols and potential cost implications warrant consideration against alternative strategies such as targeted selective treatment or extended dosing intervals.
Read the full abstract on PubMed
Practical Takeaways
- •Using piperonyl butoxide as a metabolic inhibitor with oxfendazole substantially improves anthelmintic efficacy in horses and may help combat resistant parasite populations
- •Combined OFZ + PB treatment eliminated mature nematodes and reduced larval stages more effectively, potentially extending the useful lifespan of benzimidazole drugs in your parasite control programme
- •Consider metabolic inhibitor combinations as a strategy when resistance to standard anthelmintics is suspected or when treating difficult-to-eliminate migrating larval stages
Key Findings
- •Piperonyl butoxide co-administration increased oxfendazole Cmax 3-fold and AUC 5-fold in plasma
- •Oxfendazole + piperonyl butoxide achieved 100% efficacy against mature nematodes compared to oxfendazole alone
- •Efficacy against cyathostome L3 larvae increased from 94% to 98.7% with piperonyl butoxide co-treatment
- •L4 larvae recovery was significantly reduced from 1397 to 146 when oxfendazole was combined with piperonyl butoxide (P<0.05)